Psychedelic Stocks,Shroom News Lexston Launches Psychedelic Mushroom Genetic Identification Test By Dennis Mutua January 25, 2022 Biotechnology company engaging in contact based cannabis research and analytical testing to help licensed producers in cultivation, processing and extraction of naturally derived compounds Lexston Life Sciences Corp. (CSE: LEXT) (...
Featured,Shroom News Psygen Granted License to Become First Dedicated Psychedelics Manufacturing Facility in Canada By Dennis Mutua January 21, 2022 Manufacturer of pharmaceutical-grade psychedelic drug products for clinical research and therapeutic applications Psygen Labs announced having been granted a dealer’s license by Heath Canada to become Canada’s first dedicated ...
Psychedelic Stocks,Shroom News Numinus Submits Clinical Trial Application For Naturally Extracted Psilocybe Formulation NBIO-01 By Dennis Mutua January 17, 2022 Mental health and wellness company focusing on administering psychedelic medicine with holistic integrated psychotherapy Numinus Wellness Inc. (TSX: NUMI) has submitted clinical trial application (CTA) to Health Canada for the Pha...
Psychedelic Stocks,Shroom News Mydecine Completes Supercomputing AI Modeling for Psychedelic Drug Development By Dennis Mutua January 11, 2022 Biotechnology company specializing in research, development and acceptance of naturally extracted medicine for better clinical trial management and mental health welfare Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) ann...
Featured,Shroom News Stephen Hurst Steps Down From MindMed’s Board of Directors By Dennis Mutua January 10, 2022 Biotechnology company developing and deploying psychedelic inspired medicines to treat addiction and mental conditions MindMed Inc. (NASDAQ: MNMD) (NEO: MMED) announced Stephen Hurst has resigned from his position as a director to...
Psychedelic Stocks,Shroom News MindMed Announces Completion of Phase 1 Clinical Trial of 18-MC By Dennis Mutua January 05, 2022 Psychedelic medicine company focusing on discovering, developing and deploying psychedelic-inspired medicine to cure addiction and mental illnesses MindMed Inc. (NASDAQ: MNMD) (NEO: MMED) announced having successfully completed ph...
Psychedelic Stocks,Shroom News Numinus Wellness Commends Health Canada for Amending SAP Allowing Access to Psychedelic Medicine By Dennis Mutua December 31, 2021 Mental health and wellness company combining the practice of administering psychedelic medicine with holistic integrated psychotherapy Numinus Wellness Inc. (TSX: NUMI) has applauded Health Canada for amending Special Access Progr...
Psychedelic Stocks,Shroom News HAVN Life Sciences Enters Into an Agreement to Acquire Spore Life Sciences By Dennis Mutua December 21, 2021 Biotechnology company focusing on psychedelic therapies for treatment HAVN Life Sciences Inc. (CSE: HAVN) (OTCMKTS: HAVLF) announced having entered into a definitive agreement to acquire all outstanding securities of Spore Life Sc...
